Overview:<\/strong> Methocarbamol is a centrally acting medicine used for painful musculoskeletal conditions. This page concerns oral tablets containing methocarbamol alone. It is not an instruction for an injection or a combination pain medicine. Its exact mechanism in humans is uncertain, and its benefit may partly relate to central nervous system depression rather than a direct action on skeletal muscle.<\/p>\n Uses and formulation:<\/strong> The reviewed US tablet label describes use alongside rest, physical therapy and other measures for acute, painful musculoskeletal conditions. Persistent pain or spasm should be reassessed rather than managed by unplanned increases or indefinite continuation. The particular formulation, prescribed schedule and other treatments should be checked with the treating professional.<\/p>\n Safety:<\/strong> Drowsiness, dizziness, nausea and visual or coordination problems have been reported; the label does not establish a precise frequency for every reaction. Alcohol increases the concern about impairment. Severe sleepiness, breathing difficulty, fainting, seizures or a serious allergic reaction require urgent assessment. Pregnancy safety has not been established, and human milk transfer is unknown. Kidney or liver disease can affect the treatment assessment.<\/p>\n Drug interactions:<\/strong> Other central nervous system depressants can add to sedation and impaired performance. A UK oral product document also warns that antimuscarinic effects may be potentiated. Methocarbamol can reduce the effect of pyridostigmine, which is especially relevant in myasthenia gravis; the UK label lists that condition as a contraindication whereas the reviewed US label gives a precaution. Do not change a muscle relaxant, sleeping medicine or myasthenia treatment without professional advice.<\/p>\n This page provides an English summary of the cited sources. Source check: Sources<\/h2>\n
\n